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Abstract
Irreversible cartilage collagen breakdown by the collagenolytic matrix metalloproteinases
(MMPs)-1 and MMP-13 represents a key event in pathologies associated with tissue
destruction such as arthritis. Inflammation is closely associated with such pathology and
occurs in both rheumatoid and osteoarthritis making it highly relevant to the prevailing tissue
damage that characterises these diseases. The inflammation-induced activating protein-1
(AP-1) transcription factor is an important regulator of both MMP1 and MMP13 genes with
interplay between signalling pathways contributing to their expression. Here, we have exam-
ined the regulation of MMP1 expression, and using in vivo chromatin immunoprecipitation
analyses we have demonstrated that cFos bound to the AP-1 cis element within the proxi-
mal MMP1 promoter only when the gene was transcriptionally silent as previously observed
for MMP13. Subsequent small interfering RNA-mediated silencing confirmed however, that
cFos significantly contributes to MMP1 expression. In contrast, silencing of ATF3 (a prime
MMP13 modulator) did not affect MMP1 expression whilst silencing of the Wnt-associated
regulator cysteine- serine-rich nuclear protein-1 (CSRNP1) resulted in substantial repres-
sion of MMP1 but not MMP13. Furthermore, following an early transient peak in expression
of CSRNP1 at the mRNA and protein levels similar to that seen for cFOS, CSRNP1 expres-
sion subsequently persisted unlike cFOS. Finally, DNA binding assays indicated that the
binding of CSRNP1 to the AP-1 consensus-like sequences within the proximal promoter
regions of MMP1 and MMP13 was preferentially selective for MMP1 whilst activating tran-
scription factor 3 (ATF3) binding was exclusive to MMP13. These data further extend our
understanding of the previously reported differential regulation of these MMP genes, and
strongly indicate that although cFos modulates the expression of MMP1/13, downstream
factors such as CSRNP1 and ATF3 ultimately serve as transcriptional regulators in the con-
text of an inflammatory stimulus for these potent collagenolytic MMPs.
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Introduction
Degenerative joint diseases result in destruction of the articular cartilage, typically when a vari-
ety of pro-inflammatory mediators perpetuate the disease process (reviewed in [1]). There is
now increasing evidence that such inflammatory mediators are involved the pathogenesis of
both rheumatoid arthritis (RA) and osteoarthritis (OA) [1]. These mediators include interleu-
kin (IL)-1, members of the IL-6 family (including IL-6 and oncostatin M (OSM)) as well as
other inducers of signalling such as Wnt [2–4]. Cartilage collagen breakdown is well docu-
mented to be primarily due to the matrix metalloproteinases (MMPs), in particular the collage-
nases MMP-1 and MMP-13, which are responsible for the irreversible degradation of the
collagenous matrix [5]. Although dogma suggests MMP-1 is the major collagenase in RA,
whilst MMP-13 prevails in OA, the above mediators all drive the expression of both MMPs
with MMP1 induction typically more marked [6, 7]. Furthermore, we have previously reported
differential regulatory mechanisms for cytokine-induced MMP1 and MMP13 expression in
human chondrocytes [8, 9], and recently confirmed that the most potent cytokine stimulus
reported promotes many signalling pathways that are common to a wide variety of pro-inflam-
matory stimuli [10]. Indeed, we and others have demonstrated marked MMP expression in
chondrocytes stimulated with numerous inflammatory mediators [11–15] indicating such
potent expression occurs within most inflammatory situations associated with tissue destruc-
tion such as RA and OA. Consequently, the collagenases represent key therapeutic targets for
disease-modifying agents [5, 16].
Investigations of the molecular mechanisms by which MMPs are regulated [17, 18] have
highlighted a primary role for activator protein (AP)-1 transcription factor complexes in regu-
lating MMP expression [9, 19–21]. AP-1 exists as a protein dimer found ubiquitously through-
out different tissues and cell types and is comprised of FOS and JUN family heterodimers.
Many studies [13, 22–24], including our own [9, 17, 25], have indicated that cFos/cJun AP-1
heterodimers act as critical regulators of MMP1 and MMP13 in chondrocytes following pro-
catabolic stimuli such as IL-1+OSM. Interestingly, despite the importance of cFos (gene name
FOS), differential regulation of MMP1 and MMP13 via specific cell signalling pathways [8, 9,
13–15, 24, 26] suggests more complex mechanism(s) underpin the transcriptional activation of
these MMPs. In this context, we have recently shown that MMP13 expression is initially mod-
ulated by a transient expression of cFos, which subsequently results in the prolonged expres-
sion of activating transcription factor 3 (ATF3) to promote MMP13 expression via an AP-1 cis
element within the MMP13 proximal promoter [10].
In order to expand our understanding of MMP1 regulatory mechanisms, MMP1 regulation
was assessed following the same potent pro-catabolic stimulus as detailed above for MMP13.
Data herein indeed confirm that cFos silencing was sufficient to significantly inhibit MMP1
expression; however, ATF3 silencing did not affect MMP1 expression. Importantly, IL-1
+OSM stimulation induced cysteine- serine-rich nuclear protein-1 (CSRNP1; also termed
Axin upregulated-1 (AXUD1)), expression to selectively modulate MMP1 in human chondro-
cytes. CSRNP1 was first identified as being induced by the β-catenin regulator, AXIN1[27],
and has subsequently been characterised as a transcription factor having a role in the regula-
tion of Wnt signalling[28]. In this respect the Wnt/β-catenin signalling cascade pathway has
recently been shown to play an important regulator in the onset and progression of OA[29].
This is the first report indicating a role for CSRNP1 in modulating the expression of a chon-
drogenic collagenase due to an inflammatory insult, and may be indicative of diverse regula-
tory moieties affecting specific MMP gene transcription as a consequence of inflammation
associated with OA progression.
Cytokine-induced cysteine- serine-rich nuclear protein-1 (CSRNP1) and MMP1 expression
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Materials and methods
Materials
All chemicals were of the highest purity available and obtained from Sigma Chemical Co
(Poole, UK) unless otherwise stated. All cytokines were recombinant human. IL-1α was a gen-
erous gift from Dr Keith Ray (GlaxoSmithKline, Stevenage, UK). OSM was prepared in-house
as described [30]. siRNA reagents were screened for toxicity using the Toxilight assay of ade-
nylate kinase release (Lonza, Wokingham, UK).
Chondrocytes
Human chondrocytes were isolated by enzymatic digestion of macroscopically normal articu-
lar cartilage from OA patients undergoing joint replacement surgery as described [31]. All sub-
jects gave informed consent and the study was approved by the Newcastle and North Tyneside
Joint Ethics Committee. Chondrocytes were maintained in Dulbecco’s modified Eagle’s
medium supplemented with 10% foetal bovine serum, 100 IU/mL penicillin, 100 μg/mL strep-
tomycin, 40 U/mL nystatin.
Gene expression analyses
RNA was typically stabilised in cell lysates in a 96-well format and cDNA synthesised using the
Cells-to-Signal kit (Life Technologies) as directed. SYBR Green real-time PCR or Taqman
assays (using Universal Probe Library probes (Roche Applied Sciences)), referred to herein as
qPCR, were conducted using primers and conditions described previously [8–10] except for
MMP1: For, 5’-CGAATGGCTCATTAAATCAGTTATGG-3’ and Rev, 5’-TATTAGCTCTAG
AATTACCACAGTTATCC-3’, Probe, FAM-CAGAGAGTACAACTTACA TCGTGTTGCGG
CTC-TAMRA; MMP1 (proximal promoter/transcription start site): For, 5’-TCAGTA-
CAGGTGCCGAACAG-3’ and Rev, 5’-CAAGATGTGTGCGAAGGAGA-3; MMP1 (3’ untrans-
lated region): For, 5’-ACTGAATGGGCAAAAACTGG-3’ and Rev, 5’-TGCAAACAGGGA
CAATTTGA-3’; CSRNP1: For, 5’-CCTGCCTGACCGTGACTT-3’ and Rev, 5’-
AGCCCGCTTCAGGATAGAC-3’, Probe: 57. Nascent hnRNA transcript expression of MMP1
was determined via reverse transcription and Taqman employing 50-TTTCTTGATTGGCA
GGGAA-30 (For) and 50-GGAAGCCAAAGGAGCTGTA-30 (Rev) primers spanning the Exon8/
Intron7 boundary with probe number 26.
Chromatin immunoprecipitation (ChIP)
ChIP experiments were performed according to the standard protocol detailed in the EZ-ChIP
kit (Merck-Millipore). Briefly, human chondrocytes were cultured until 70–80% confluent at
which point they were treated with IL-1 (0.05 ng/mL) in combination with OSM (10 ng/mL)
for various durations. Cells were then subject to cross-linking with formaldehyde for 5 min
with agitation, and the reaction quenched with 0.125 M glycine for 5 min (with agitation).
Cells were then washed twice and scraped into PBS supplemented with protease inhibitors.
Cells were pelleted, resuspended in lysis buffer and lysates sonicated in a Bioruptor Plus (Diag-
enode, Liege, Belgium) sonicating water bath (15 cycles of 30 sec on, 30 sec off at full power) to
shear the chromatin. Samples were then pre-cleared with the appropriate agarose beads for 1 h
and subject to an overnight immunoprecipitation with relevant antibodies (10 μg) or corre-
sponding isotype controls; anti-phospho-RNA polymerase II CTD repeats YSPTSPS (Ser5;
pRNA Pol II) was from Abcam (Cambridge, UK); anti-acetyl(Lys9/14)-histone H3 (AcH3; cat
no. 06–599) was from Millipore (Dundee, UK). Antibody/protein/DNA complexes were
extracted with agarose beads which were washed sequentially with kit-supplied buffers. DNA
Cytokine-induced cysteine- serine-rich nuclear protein-1 (CSRNP1) and MMP1 expression
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was then eluted and crosslinks reversed (4 h incubation at 65 ˚C with 5 M NaCl, and then 1 h
incubation at 37 ˚C with RNase (1 IU) and proteinase K (1 IU) to degrade RNA and protein,
respectively). DNA was purified using spin columns and then used as input for SYBR green
qPCR using primers outlined above. Data were normalised to background using isotype con-
trol antibodies and variations in amount of genomic DNA were normalised using Input.
Gene promoter profiling
In silico analyses on ChIPSeq (cJun) MMP1/13 data [32] to identify the presence of putative
CSRNP1 binding sites (AGAGTN [33]) were performed using ENCODE [34].
Cell fractionation and immunoblotting
Chondrocyte lysates were prepared as described previously [8, 31]. In some experiments chon-
drocytes were subjected to subcellular fractionation using NE-PER Nuclear and Cytoplasmic
Protein Extraction Kit or Subcellular Protein Fractionation Kit (both from ThermoFisher Sci-
entific, Loughborough, UK). Lysates or fractions were resolved by SDS-PAGE, transferred to
PVDF membranes and subsequently probed with the following antibodies: ATF3 (sc188) and
CSRNP1 (sc81191) (used on cellular fractionation and experiments utilising nuclear lysates)
purchased from Santa Cruz Biotechnology (Santa Cruz, CA); and CSRNP1 (ab103708) (used
on whole cell lysates) from Abcam (Cambridge, UK). The specificity of all antibodies was con-
firmed using chondrocyte lysates (see full-length blots in S1 Fig), whilst blots were cropped for
clarity of comparison.
Cell transfection and RNA interference
Primary human chondrocytes were prepared and cultured as above, and transfected as
described previously [8]. Dharmacon ON-TARGET plus SMARTpool (ThermoFisher Scien-
tific, Loughborough, UK) of 4 specific siRNA duplexes (100 nM siRNA final concentration)
were used throughout to assess IL-1+OSM-induced MMP1 expression. All siRNAs used were
as previously described [10] except for CSRNP1 (Cat. L-013653; Dharmacon), BMP2 (Cat. L-
011219; Dharmacon), IER2 (Cat. L-019884; Dharmacon) and IER5 (Cat. L-013467; Dharma-
con). Following transfection, cells were stimulated for 1.25 h to measure transcriptional regula-
tors, or 24 h for MMP1. Depletion of gene-specific mRNA levels was calculated by comparison
of expression levels with cells transfected with 100 nM siCONTROL (siCon: non-targeting
siRNA #2, Cat. 001210–02; Dharmacon).
DNA affinity precipitation assays (DAPA)
Chondrocyte nuclear lysates were generated as described above. Nuclear protein (100–300 μg)
was incubated with double stranded biotinylated oligonucleotides (45 pmol) containing either
the proximal AP-1 binding site for MMP1 (5’-[biotin]-TAAAGCATGAGTCAGACA
CCT-3’; 5’-AGGTGTCTGACTCATGCTTTA-3’) or MMP13 (5’-[biotin]-TAAGTG
ATGACTCACCATTGC-3’; 5’-GCAATGGTGAGTCATCCTTA-3’) in 500 μl of binding
buffer (12 mM HEPES pH 7.9, 4 mM Tris-HCl, 60 mM KCl, 5% (w/v) glycerol, 0.5 mM
EDTA, 1 mM DTT and 1 mini protease inhibitor cocktail tablet/10 mL of buffer) for 1 h at 4
˚C with rotation. Streptavidin-coated magnetic dynabeads (ThermoFisher Scientific) were
then added and incubated for 2 h with rotation at 4 ˚C. Dynabead-bound protein/DNA com-
plexes were isolated using a Dynabead magnet (ThermoFisher Scientific). Beads were resus-
pended in 50 μl of SDS-PAGE sample buffer, incubated at 100 ˚C for 5 min, pelleted and
supernatants removed for immunoblotting (as above) except that each individual blot was cut
to provide two blots with proteins of molecular mass�35kDa or�35kDa for CSRNP1 and
Cytokine-induced cysteine- serine-rich nuclear protein-1 (CSRNP1) and MMP1 expression
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ATF3 probing, respectively. Specificity of binding was determined in the presence of 50x
excess non-biotinylated AP-1 oligonucleotides.
Statistical analyses
Statistical differences between sample groups were assessed using one-way analysis of variance
(ANOVA) with a post-hoc Bonferroni’s multiple comparison test or Student’s 2-tailed
unpaired t-test, where ���p<0.001, ��p<0.01, �p<0.05. For clarity, only selected comparisons
are presented in some figures.
Results
MMP1 gene expression is temporally delayed in cytokine-stimulated
chondrocytes
We have previously shown that the potent cytokine combination of IL-1+OSM demonstrates a
time-dependency for collagenolytic MMP induction, typically reaching maximal induction at 24
h [6, 7, 35]. This dependency is confirmed here where primary human articular chondrocytes
expressed MMP1 mRNA within 6 h post-stimulation (Fig 1A) in line with previous findings [7].
Importantly, nascent hnRNA mirrored the observed mRNA increase (Fig 1B) indicating MMP1
transcription occurred independently of mRNA synthesis/stability. Furthermore, previous data
indicate that cFOS is rapidly, but transiently, expressed following IL-1+OSM stimulation [10,
25]; employing ChIP assays herein cFos was observed to be enriched at the proximal AP-1 ele-
ment of the MMP1 promoter at 1 h post-stimulation (Fig 2A and 2B). However, ChIP assays
also confirmed enhanced enrichment of phosphorylated RNA Pol II to the proximal MMP1 pro-
moter 24 h post-stimulation, but not at 1 h (Fig 2C and 2D), whilst the time-dependent recruit-
ment of acetylated histone H3 to the MMP1 promoter (Fig 2E) reflected the observed time
course of MMP1 mRNA expression. Our previous data indicated a requirement for new protein
synthesis for MMP13 induction [10] by employing the protein synthesis inhibitor emetine. Simi-
larly, in this study chondrocytes were stimulated for 24 h with IL-1+OSM and emetine added
subsequently for varying durations throughout the stimulation which significantly reduced cyto-
kine-induced MMP1 expression and persisted for at least 6–8 h post-stimulation (Fig 3).
Given the discord between the transient increase of cFos by IL-1+OSM [9, 10, 25] and the
requirement for new protein synthesis at times after cFos expression in terms of MMP1
expression, these findings strongly indicated the requirement of additional transcriptional reg-
ulator(s) as shown for the expression of MMP13 [10]. Employing a GEO-genome-wide analy-
sis of IL-1+OSM-induced genes in chondrocytes (accession file GSE86578), we further
confirmed that the temporal expression profile of MMP1 was maximal at 24 h (Fig 4A) whilst
qPCR confirmed significant expression at 24h in these populations (Fig 4B). Moreover, this
gene array analysis identified a number of transcriptional regulatory genes with an expression
profile similar to ATF3 which has been shown to be an important AP-1-binding factor for
MMP13 expression [10]. A siRNA screen of these regulators, including ATF3, to assess MMP1
repression confirmed a requirement for both FOS (cFos) and JUN (cJun) but not ATF3 for
MMP1 expression (Fig 4C). Notably, only silencing of CSRNP1 selectively and significantly
repressed MMP1 with no significant inhibition of MMP13 (S2 Fig).
Sustained CSRNP1 expression contributes toMMP1 transcription
The siRNA data above implicated a selective role for CSRNP1 in contributing to the transcrip-
tional activation of MMP1 (but not MMP13). Furthermore, expression profiling also revealed
that CSRNP1 expression was evident by 1 h and peaked at 1.25 h (Fig 5A and 5B). In order to
Cytokine-induced cysteine- serine-rich nuclear protein-1 (CSRNP1) and MMP1 expression
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correlate CSRNP1 expression with FOS, a detailed time-course was performed which showed
peak CSRNP1 expression to follow maximal FOS expression (Fig 5C). Importantly, CSRNP1
protein was present from 1 to 24 h (Fig 6A–6C) and appeared to be exclusively nuclear (both
soluble and chromatin-bound fractions) following subcellular fractionation (Fig 6C), peaking
at 3 h (Fig 6B and 6D).
In silico analyses using the ENCODE database [34] indicated that a consensus-like CSRNP1
motif AGAGTN [33] was present within the proximal ChIPSeq AP-1 (cJun) binding site
within the MMP1 promoter, with a 1 bp mismatch. We therefore performed DAPA analyses
which, importantly, confirmed specific CSRNP1 binding to this sequence, compared to the
equivalent motif within MMP13 (Fig 7), thus further confirming the selective specificity of
Fig 1. IL-1+OSM-inducedMMP1mRNA expression is preceded by nascent hnRNA formation. Chondrocytes were stimulated
with IL-1 (0.05 ng/mL) in combination with OSM (10 ng/mL) for the indicated durations. Total RNA was isolated, reverse
transcribed and subjected to qPCR for (A) MMP1 mRNA or (B) MMP1 nascent hnRNA as described in the Materials and Methods.
Data are expressed relative to 18S rRNA and presented as fold increase compared to basal expression. qPCR data (n = 4) are
representative of at least three separate chondrocyte populations. All data are presented as mean (± SD), where ���, p<0.001; ��,
p<0.01; �, p<0.05 IL-1+OSM-treated compared to control; ANOVA.
https://doi.org/10.1371/journal.pone.0207240.g001
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CSRNP1 for MMP1. Finally, we also assessed the ability of the MMP1/13 AP-1 sequences to
bind ATF3 and only observed binding to the MMP13 AP-1 cis element (Fig 7) in line with pre-
vious findings [10].
Discussion
Recent evidence indicates that IL-1+OSM-induces MMP13 expression via transcriptional
modulation by initial AP-1 (cFos) expression and then by subsequent ATF3 transcriptional
activity [10]. In this context, the transcriptional regulation of MMP1, which is also potently
induced by this stimulus [6–9, 35–37], has remained undefined. Although MMP-13 is the
most potent collagenolytic proteinase against type II collagen [38], the abundance of MMP-1
Fig 2. ChIP analyses of theMMP1 proximal promoter. Human chondrocytes were treated with IL-1 (0.05 ng/mL) in combination with OSM (10 ng/
mL) for the indicated durations. Cells were then subject to DNA-protein cross-linking, lysis and DNA shearing. Immuno-precipitation for cFOS (A,B),
pRNA Pol II (C,D) or AcH3 (E) was followed by isolation of complexed genomic DNA and qPCR for the proximal (closed bars) and 3’-UTR (used for
normalization; open bars) regions of MMP1 as indicated. Data (mean ± SD, n = 4) are pooled from at least three separate chondrocyte populations from
different donors. Statistical comparisons are: #, p<0.05 (1 h IL-1+OSM stimulation versus basal); �, p<0.05 (24 h IL-1+OSM stimulation versus basal).
https://doi.org/10.1371/journal.pone.0207240.g002
Cytokine-induced cysteine- serine-rich nuclear protein-1 (CSRNP1) and MMP1 expression
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compared to MMP-13 following pro-inflammatory stimuli [35, 37, 39] also results in signifi-
cant cleavage of type II collagen resulting in irreversible cartilage damage [40]. Since MMP1
and MMP13 appear to be differentially regulated following IL-1+OSM stimulation [8, 9, 26],
in the study presented herein we sought to identify transcriptional modulators that are selec-
tive for MMP1 in comparison to our previous observations for MMP13 [10].
Employing ChIP assays with cFos, phosphorylated RNA Pol II and acetylated histone H3
antibodies, we demonstrated that cFos transcriptional control was similarly important for reg-
ulating MMP1 expression as observed for MMP13 [10]. cFOS was recruited to the MMP1 pro-
moter 1 hour post-stimulation, however pRNA pol II was not detected at this timepoint,
rather being recruited to the promoter 24 hours post-stimulation. These data indicate that
despite cFOS recruitment to the MMP1 promoter, MMP1 transcription does not occur at this
early time point. Furthermore, the inhibition of protein synthesis after IL-1+OSM stimulation
demonstrates that when protein synthesis is inhibited within the first 4 hours of stimulation,
no MMP1 expression is observed 24 hours post-stimulation. However if protein synthesis is
not inhibited until after 6 hours of IL-1+OSM, MMP1 expression is observed following 24
hour stimulation. The requirement for the de novo synthesis of transcriptional regulators fol-
lowing cell activation has been previously reported in the literature [10, 41, 42]. Taken
together, these data strongly suggest that MMP1 expression is dependent on de novo protein
synthesis of additional factors post-FOS but prior to MMP1 expression.
In order to identify such factors, GEO-genome-wide microarray analyses with subsequent
siRNA assays were performed. These studies identified several transcriptional regulators
which had an elevated expression level 1–1.25 hours post IL-1+OSM stimulation. In compar-
ing the effect of siRNA knock down of these transcriptional regulators on MMP expression
[10], only CSRNP1 was found to be selective and specific for the regulation of MMP1 expres-
sion over MMP13. This study indicated that MMP1 expression was indeed dependent on cFos
but that other FOS family members also affected MMP1 expression via promoting AP-
1-dependent gene expression. In this respect, FOSL1 and FOSB were induced (see S3 Fig) and
gene silencing of both resulted in significant MMP1 repression. These analyses are also in
Fig 3. IL-1+OSM-inducedMMP1 expression is dependent on new protein synthesis. Chondrocytes were treated with IL-1 (0.05
ng/mL) and OSM (10 ng/mL) for 24 h. Emetine (10 μM final concentration) was added at the indicated times after initiation of IL-1
+OSM stimulation and qPCR performed on extracted RNA. Relative expression levels of MMP1 mRNA were normalized to 18S
rRNA, where ###, p<0.001 (IL-1+OSM vs basal); ���, p<0.001 (IL-1+OSM+emetine vs basal). Data (mean ± SD, n = 6) are
representative of three separate experiments each using chondrocyte cultures from different donors.
https://doi.org/10.1371/journal.pone.0207240.g003
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agreement with other studies indicating a role for cytokine induction of the NFκB component
RelA (p65) for MMP1 expression in chondrocytes [15, 43–45]. We show here that siRNA
silencing of RELA leads to a significant decrease in MMP1 expression although to a much
lesser extent than seen for FOS or FOSL1.
Fig 4. IL-1+OSM-inducedMMP1 expression is maximal at 24 h post-stimulation. Human chondrocytes were
treated with IL-1 (0.05 ng/mL) in combination with OSM (10 ng/mL) for the indicated time points and total RNA
isolated. (A) RNA from three separate populations (#1, #2 and #3) was profiled using the Human HT-12v4 Expression
Beadchip. The expression profile for MMP1 from the microarray dataset for each chondrocyte population is shown.
(B) RNA from six separate chondrocyte populations was subjected to qPCR for MMP1, and relative expression levels
(normalized to 18S rRNA) at the indicated times determined. The plots show mean ± SD (n = 6). Data from the
populations used in the microarray analyses are highlighted by the solid symbols (#1,▲; #2■; #3,●). (C) Prior to
stimulation with IL-1 (0.05 ng/ml) in combination with OSM (10 ng/ml), human chondrocytes were transfected with
siRNA specific for the indicated genes, or a non-targeting control (siCon; all 100 nM), and mRNA expression levels
(mean ± S.D., n = 6) of MMP1 measured 24 h post-stimulation by qPCR, relative to siCon treated cells, normalized to
18S rRNA. Statistical comparisons are versus IL-1 + OSM + siCon (Student’s two-tailed unpaired t test), where ���,
p<0.001; ��, p<0.01; �, p<0.05; ns = not significant. The data are pooled from three separate experiments, each using
chondrocyte cultures from different donors.
https://doi.org/10.1371/journal.pone.0207240.g004
Cytokine-induced cysteine- serine-rich nuclear protein-1 (CSRNP1) and MMP1 expression
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Fig 5. IL-1+OSM induces sustained expression of CSRNP1 mRNA. Human chondrocytes were treated with IL-1 (0.05 ng/
mL) in combination with OSM (10 ng/mL) for the indicated time points and total RNA isolated. (A) RNA from three
separate populations (#1, #2 and #3) was profiled using the Human HT-12v4 Expression Beadchip. The expression profile
for CSRNP1 from the microarray dataset for each chondrocyte population is shown. RNA from 6 (B) or 3 (C) separate
chondrocyte populations was subjected to qPCR for FOS (C) or CSRNP1 (B and C), and relative expression levels
(normalized to 18S rRNA or GAPDH as indicated) at the indicated times determined. The plots show mean ± SD. Data from
the populations used in the microarray analyses in (A) are highlighted by the solid symbols (#1,▲; #2■; #3,●). (C)
Statistical comparisons are: ���, p<0.001; ��, p<0.01; �, p<0.05 versus basal.
https://doi.org/10.1371/journal.pone.0207240.g005
Cytokine-induced cysteine- serine-rich nuclear protein-1 (CSRNP1) and MMP1 expression
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Fig 6. IL-1+OSM induces nuclear expression of CSRNP1. Human chondrocytes were stimulated with IL-1 (0.05 ng/
mL) in combination with OSM (10 ng/mL) for the indicated durations. Protein from either whole cell lysates (A) or
subcellular fractions (C: a, cytosolic; b, membrane-bound; c, soluble nuclear; d, chromatin-bound; e, cytoskeletal) were
resolved using SDS-PAGE and immunoblotted with an antibody to CSRNP1. Combined densitometric scans of
separate blots for CSRNP1 in cell lysates (n = 3; B) or pooled soluble and chromatin-bound nuclear fractions (n = 5;
D), relative to t = 0 h, are shown and were obtained from separate chondrocyte populations. All data are presented as
mean (± SD), where ��, p<0.01, IL-1+OSM-treated compared to control; ANOVA.
https://doi.org/10.1371/journal.pone.0207240.g006
Cytokine-induced cysteine- serine-rich nuclear protein-1 (CSRNP1) and MMP1 expression
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Little is known about the role of CSRNP1 as a transcriptional regulator. Here we provide
the first evidence that CSRNP1 has an important modulatory role in affecting cytokine-
induced MMP1 expression in human articular chondrocytes. The consensus sequence for
CSRNP1 binding is an AP-1-like binding motif 5’-AGAGTN-3’ [33] and both MMP1 and
MMP13 have similar AP-1-like binding motifs within their proximal promoter regions. The
MMP1 sequence is 5’-TGAGTCA-3’ and the MMP13 sequence has a C instead of a G (under-
lined) resulting in 5’-TGACTCA-3’. This G to C switch indicates preferential binding of
CSRNP1 to the MMP1 compared to the MMP13 AP-1-like cis element as observed via DAPA
analyses. This may be indicative that the proximal MMP1 AP-1-like sequence is a specific cis
element capable of binding CSRNP1 in chondrocytes. Furthermore, in silico analysis indicates
the presence of other putative CSRNP1 binding sites located within the MMP1 proximal pro-
moter, but not within MMP13, that may also contribute to the expression of MMP1. Since no
evidence for reproducible ATF3 binding to the MMP1 AP-1 cis element was observed employ-
ing DAPAs in contrast to MMP13, and gene silencing of ATF3 resulted in no significant
decrease in MMP1 expression, MMP1 appears unlikely to be an ATF3-responsive gene. Thus,
CSRNP1 and ATF3 may respectively have mutually exclusive roles in the cytokine-mediated
expression of MMP1 and MMP13 in chondrocytes.
In conclusion, our data presented here indicate that a potent catabolic stimulus such as IL-1
+OSM induces the expression of specific transcriptional regulators that contribute to MMP1
gene activation which may well reflect the markedly enhanced levels of expression that are
observed compared to either cytokine alone [35, 39]. Since multiple pro-inflammatory media-
tors are likely to be prevalent in most inflammatory situations, this study further highlights the
complexity of MMP gene regulation that occurs in human chondrocytes when subjected to
inflammatory cues.
Supporting information
S1 Fig. Confirmation of antibody specificity using human chondrocyte lysates. The speci-
ficity of each antibody used in the study was confirmed using nuclear lysates prepared as
described in the Methods from primary human articular chondrocytes either unstimulated or
Fig 7. CSRNP1 selectively binds the proximalMMP1AP-1 motif at a transcriptionally active time-point in IL-1+OSM-
stimulated chondrocytes. Human chondrocytes were treated with IL-1 (0.2 ng/mL) in combination with OSM (10 ng/mL) for 3 h.
Nuclear lysates were prepared and subjected to either Western blotting alone (input) or DAPA with CSRNP1 or ATF3 antibodies, as
described in the Materials and Methods. Non-biotinylated AP-1 oligonucleotides (50x excess; Comp) were used to confirm
specificity of binding in the DAPAs. The data are representative of 3–5 separate experiments each using chondrocyte cultures from
different donors.
https://doi.org/10.1371/journal.pone.0207240.g007
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stimulated with IL-1 (0.2 ng/mL) in combination with OSM (10 ng/mL). Following
SDS-PAGE, proteins were transferred to PVDF membranes and probed with the indicated
antibodies. Full-length blots are presented to highlight the specific immuno-reactivity of each
antibody with an arrow indicating the expected molecular mass.
(TIF)
S2 Fig. Multiple transcriptional regulators impact on MMP13 gene expression. Following
transfection with siRNA specific for the indicated genes or non-targeting control (siCon; all
100 nM), Human chondrocytes were treated with IL-1 (0.05 ng/ml) in combination with OSM
(10 ng/ml) for 24 hours. RNA isolated from three separate populations were subjected to
qPCR, relative to siCon control normalised to 18S rRNA. Statistical comparisons are: ���,
p<0.001; ��, p<0.01; �, p<0.05; ns = not significant, versus siCon. The effect of silencing
ATF3, FOS, FOSB, FOSL1, IER3, IRF1, JUN and RELA on MMP13 expression was originally
published in the Journal of Biological Chemistry. Chan et al. (2017)[10], Copyright the Ameri-
can Society for Biochemistry and Molecular Biology.
(TIF)
S3 Fig. Multiple transcriptional regulators are induced following IL-1+OSM stimulation
of human chondrocytes. Human chondrocytes were treated with IL-1 (0.05 ng/mL) in combi-
nation with OSM (10 ng/mL) for 1, 1.25 or 24 h and total RNA isolated. RNA from three sepa-
rate populations (#1, #2 and #3 as presented in Figs 4 and 5) was profiled using the Human
HT-12v4 Expression Beadchip. The MMP1 expression profile reported in Fig 4 is presented
here for comparison with the profiles of the indicated genes from the microarray dataset for
each chondrocyte population.
(TIF)
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